综合性分析确定TEAD4是人类癌症的普遍预后生物标志物
Mohan Liu1, Yang Song2, Yue Kang3
1Department of Biochemistry and Molecular Biology, School of Life Sciences, China Medical University, Shenyang, China.
Frontiers in immunology
|October 16, 2025
概括
在许多癌症中,TEA域转录因子4 (TEAD4) 过度表达,促进癌症的进展和耐治疗性. 这项研究强调TEAD4作为预后生物标志物和改善癌症患者治疗结果的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- TEA域转录因子4 (TEAD4) 是一种涉及瘤发生的河马途径效应因子.
- 对TEAD4的作用进行全面的泛癌分析是有限的.
研究的目的:
- 系统地评估TEAD4表达,预后价值和各种癌症的治疗影响.
- 研究TEAD4在癌细胞行为中的功能作用及其与瘤特征的关联.
主要方法:
- 对TEAD4表达和预后相关性的TCGA数据集的分析.
- 功能丰富,药物敏感性和体外检测.
- 基于TEAD4目标基因的预后模型的开发.
主要成果:
- 在多种癌症中,TEAD4过度表达与预后不佳相关.
- TEAD4促进了繁殖,迁移,茎结合和免疫逃避.
- TEAD4与基因组不稳定性,表观遗传变化和化学抵抗有关.
- 一个基于TEAD4的模型有效地分层患者的生存风险.
结论:
- TEAD4在癌症进展,治疗耐药性和患者结果方面发挥着多方面的作用.
- TEAD4是一种潜在的预后生物标志物和癌症治疗的治疗标.
- 这些发现为翻译性癌症研究提供了新的方向.
更多相关视频
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K


